Document is current

Any future updates will be listed below

Efficacy and safety of combining tislelizumab with capecitabine compared to capecitabine alone in the adjuvant treatment of biliary tract cancers: rationale and protocol design for a randomized clinical trial

Crossref DOI link: https://doi.org/10.1186/s12885-025-14367-7

Published Online: 2025-05-25

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark